New Pancreatic Cancer Pill Nearly Doubles Patient Survival Time in Clinical Trial

At the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, thousands of doctors and researchers rose to their feet for a nearly one-minute standing ovation. The applause was not for a lifetime achievement award, but for a slide displaying survival curves. The data showed that an experimental daily pill had achieved something previously thought impossible in one of medicine's most notoriously lethal diseases: it nearly doubled the survival time for patients with advanced pancreatic cancer.[1][2]

The drug, daraxonrasib, represents a fundamental shift in how oncologists approach metastatic pancreatic ductal adenocarcinoma (PDAC). For decades, patients whose cancer had spread and who had exhausted standard chemotherapy faced a grim prognosis, with life expectancy measured in mere months. The Phase 3 RASolute 302 clinical trial, which enrolled 500 patients globally, demonstrated that daraxonrasib extended median overall survival to 13.2 months, compared to 6.7 months for those receiving a second round of standard chemotherapy.[2][3]

To understand why these numbers triggered a standing ovation, one must look at the biological mechanism driving the disease. Approximately 90 to 92 percent of pancreatic cancers are fueled by mutations in the KRAS gene. In healthy cells, KRAS proteins act as molecular on-off switches that regulate cell growth and division. When mutated, these switches become permanently jammed in the 'on' position, continuously ordering the cell to multiply and form tumors.[4][5]

For over forty years, scientists considered mutant KRAS to be 'undruggable.' The protein's physical structure is remarkably smooth, lacking the deep pockets or crevices that traditional small-molecule drugs need to latch onto. Daraxonrasib bypasses this structural hurdle through a novel mechanism. Instead of attempting to bind directly to the slippery KRAS protein, the drug first attaches to a different, abundant cellular molecule called cyclophilin A.[5]

Once daraxonrasib binds to cyclophilin A, the resulting complex forms a new, bulky structure that is perfectly shaped to lock onto the active KRAS protein. This molecular wedge effectively shuts down the rogue protein's ability to send continuous growth signals. By cutting the power to the cancer cells, the drug halts tumor progression and, in many cases, causes the tumors to shrink.[3][5]

The clinical data from the RASolute 302 trial, published simultaneously in the New England Journal of Medicine, quantifies the impact of this mechanism. Beyond the doubling of overall survival, the trial measured progression-free survival—the amount of time patients lived before their cancer resumed growing. Patients taking daraxonrasib experienced a median progression-free survival of 7.2 months, compared to just 3.6 months for the chemotherapy control group.[2][3]

The physical reduction of tumor burden was equally striking. In the trial, 31.6 percent of patients receiving the targeted pill saw their tumors shrink by 30 percent or more—a metric known as the objective response rate. In contrast, only 11.2 percent of the patients on standard chemotherapy achieved a similar reduction.[2][3]

Crucially, this efficacy did not come at the cost of debilitating toxicity. Standard chemotherapy attacks all rapidly dividing cells, leading to severe systemic side effects. Because daraxonrasib specifically targets the mutant KRAS pathway, it spares more healthy tissue. While the drug is not without side effects—patients commonly reported rash, diarrhea, nausea, and mouth sores—these were generally manageable.[1][3]

The tolerability of the drug is reflected in the trial's discontinuation rates. Only 1.2 percent of patients taking daraxonrasib had to stop treatment due to severe adverse events. In the chemotherapy group, the discontinuation rate due to toxicity was nearly ten times higher, at 11.2 percent. Patients on the targeted therapy also reported a slower worsening of pain and a better preservation of their overall quality of life.[2][3]

Despite the unprecedented success of the trial, oncologists are careful to outline the limits of the current evidence. Daraxonrasib is not a cure. A median overall survival of 13.2 months, while a historic improvement over 6.7 months, still means that the disease remains fatal for the vast majority of patients. The drug extends life and improves its quality, but it does not eradicate the cancer entirely.[4][6]

Furthermore, the RASolute 302 trial only evaluated daraxonrasib as a second-line treatment—meaning it was given to patients whose cancer had already progressed after an initial round of chemotherapy. The medical community does not yet know if the drug would be more effective, or potentially curative, if administered earlier in the disease progression or as a first-line therapy before chemotherapy is ever used.[5][6]

There are also outstanding questions regarding drug resistance. Cancers are notoriously adaptable, and researchers anticipate that tumors will eventually develop workarounds to bypass the KRAS blockade created by daraxonrasib. Understanding these resistance mechanisms, and identifying other therapies that can be combined with the pill to prevent them, is the next major hurdle for researchers.[2][4]

Access to the medication remains another immediate challenge. Daraxonrasib is not yet fully approved by the U.S. Food and Drug Administration (FDA). The agency has granted the drug Breakthrough Therapy and Orphan Drug designations, and accepted its new drug application for an accelerated review in July 2026. A final regulatory decision is expected before the end of the year.[1][4]

In the interim, the drug's manufacturer, Revolution Medicines, has opened an Expanded Access Program. Often referred to as compassionate use, this pathway allows certain patients with life-threatening advanced pancreatic cancer to receive the medication before official FDA approval, provided they cannot enroll in an ongoing clinical trial.[1][6]

The implications of this breakthrough extend beyond the pancreas. KRAS mutations are not exclusive to pancreatic ductal adenocarcinoma; they are also found in approximately 40 to 45 percent of colorectal cancers and up to 30 percent of non-small cell lung cancers. Clinical trials evaluating daraxonrasib's efficacy against these other solid tumors are already underway, raising hopes that the drug could alter the landscape for multiple hard-to-treat malignancies.[4][5]

For now, the pancreatic cancer community is absorbing the reality of a genuine paradigm shift. After decades of incremental, often disappointing trials, physicians finally have a targeted therapy that directly addresses the genetic root of the disease. While the ultimate goal of a cure remains on the horizon, daraxonrasib has definitively proven that the deadliest of cancers is no longer undruggable.[1][4]